Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KNSA Stock Forecast 2025-2026
$41.67
Current Price
$3.16B
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KNSA Price Targets
+48.8%
To High Target of $62.00
+32.0%
To Median Target of $55.00
+8.0%
To Low Target of $45.00
KNSA Price Momentum
-2.0%
1 Week Change
+8.6%
1 Month Change
+93.7%
1 Year Change
+110.7%
Year-to-Date Change
-3.0%
From 52W High of $42.98
+133.8%
From 52W Low of $17.82
📊 TOP ANALYST CALLS
Did KNSA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Kiniksa is one of their latest high-conviction picks.
Latest KNSA Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, KNSA has a bullish consensus with a median price target of $55.00 (ranging from $45.00 to $62.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $41.67, the median forecast implies a 32.0% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Eva Fortea Verdejo at Wells Fargo, suggesting a 8.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KNSA Analyst Ratings
7
Buy
0
Hold
0
Sell
KNSA Price Target Range
Low
$45.00
Average
$55.00
High
$62.00
Current: $41.67
Latest KNSA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KNSA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 29, 2025 | Goldman Sachs | Paul Choi | Buy | Maintains | $55.00 |
| Oct 17, 2025 | Citigroup | Geoff Meacham | Buy | Maintains | $50.00 |
| Oct 13, 2025 | Wedbush | David Nierengarten | Outperform | Maintains | $44.00 |
| Sep 29, 2025 | TD Cowen | Nicholas Lorusso | Buy | Initiates | $60.00 |
| Sep 25, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $45.00 |
| Jul 29, 2025 | Jefferies | Roger Song | Buy | Maintains | $54.00 |
| Jul 9, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $42.00 |
| Apr 29, 2025 | Jefferies | Roger Song | Buy | Maintains | $45.00 |
| Apr 16, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $34.00 |
| Mar 13, 2025 | Citigroup | Geoff Meacham | Buy | Initiates | $40.00 |
| Nov 5, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $40.00 |
| Oct 30, 2024 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $35.00 |
| Sep 13, 2024 | Jefferies | Roger Song | Buy | Initiates | $40.00 |
| Jul 23, 2024 | Wedbush | David Nierengarten | Outperform | Maintains | $34.00 |
| May 3, 2024 | Wells Fargo | Eva Fortea Verdejo | Overweight | Initiates | $34.00 |
| May 1, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $30.00 |
| Apr 24, 2024 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $30.00 |
| Jan 2, 2024 | Wedbush | David Nierengarten | Outperform | Maintains | $25.00 |
| Jul 26, 2023 | Goldman Sachs | Paul Choi | Buy | Maintains | $32.00 |
| Mar 9, 2023 | JP Morgan | Anupam Rama | Overweight | Maintains | $20.00 |
Kiniksa Pharmaceuticals International plc (KNSA) Competitors
The following stocks are similar to Kiniksa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
KNSA
Kiniksa Pharmaceuticals
mkt cap
3.22B
Kiniksa Pharmaceuticals International plc (KNSA) Financial Data
Kiniksa Pharmaceuticals International plc has a market capitalization of $3.16B with a P/E ratio of 92.6x. The company generates $597.97M in trailing twelve-month revenue with a 6.0% profit margin.
Revenue growth is +61.2% quarter-over-quarter, while maintaining an operating margin of +13.3% and return on equity of +7.4%.
Valuation Metrics
Market Cap
$3.16B
Enterprise Value
$2.82B
P/E Ratio
92.6x
PEG Ratio
-0.4x
Price/Sales
5.3x
Growth & Margins
Revenue Growth (YoY)
+61.2%
Gross Margin
+53.8%
Operating Margin
+13.3%
Net Margin
+6.0%
EPS Growth
+61.2%
Financial Health
Cash/Price Ratio
+11.1%
Current Ratio
3.8x
Debt/Equity
1.8x
ROE
+7.4%
ROA
+3.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Kiniksa Pharmaceuticals International plc (KNSA) Business Model
About Kiniksa Pharmaceuticals International plc
What They Do
Develops innovative therapies for devastating diseases.
Business Model
Kiniksa Pharmaceuticals focuses on developing clinical-stage product candidates for autoinflammatory conditions. The company generates revenue by advancing its drug pipeline through clinical trials and regulatory approval processes, ultimately aiming to commercialize successful therapies that address significant unmet medical needs.
Additional Information
Headquartered in Hamilton, Bermuda, Kiniksa collaborates with medical institutions and regulatory agencies to ensure compliance and efficacy of its products. The company's focus on diseases like giant cell arteritis and chronic refractory gout highlights its commitment to addressing complex health challenges.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
315
CEO
Mr. Sanj K. Patel
Country
United Kingdom
IPO Year
2018
Website
www.kiniksa.comKiniksa Pharmaceuticals International plc (KNSA) Latest News & Analysis
Latest News
Quick Summary
Kiniksa Pharmaceuticals will present at the Jefferies Global Healthcare Conference in London on November 17, 2025, at 2:30 p.m. GMT.
Why It Matters
Kiniksa Pharmaceuticals' presentation at a major healthcare conference may signal potential updates on drug development, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage
1 month ago
Quick Summary
Kiniksa Pharmaceuticals reported Q3 FY2025 ARCALYST revenue of $180.9M, up 61% YoY. The company raised FY2025 guidance to $670–$675M, driven by increased patient-months and efficacy support.
Why It Matters
Kiniksa's strong revenue growth from ARCALYST and raised guidance indicate solid financial health, suggesting potential for sustained investor returns and confidence in future performance.
Source: Seeking Alpha
Market Sentiment:
Positive
New Strong Sell Stocks for Oct. 30th
1 month ago
Quick Summary
EQX, GDEN, and KNSA have been assigned a Zacks Rank #5 (Strong Sell) as of October 30, 2025.
Why It Matters
The addition of EQX, GDEN, and KNSA to the Zacks Rank #5 (Strong Sell) indicates declining performance expectations, signaling potential risks for investors holding these stocks.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Kiniksa Pharmaceuticals will hold its Q3 2025 earnings call on October 28, 2025, at 8:30 AM EDT. Key company executives and analysts from major firms will participate.
Why It Matters
Kiniksa Pharmaceuticals’ Q3 earnings call can signal financial health and strategic direction, impacting stock performance and investor sentiment. Analyst questions may reveal key insights into future growth.
Source: Seeking Alpha
Market Sentiment:
Neutral
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
1 month ago
Quick Summary
ARCALYST® (rilonacept) reported Q3 2025 net revenue of $180.9 million, up 61% YoY. Full-year revenue forecast raised to $670-$675 million. KPL-387 received Orphan Drug Designation. Cash balance increased to $352.1 million.
Why It Matters
Strong revenue growth for ARCALYST and raised revenue expectations indicate robust market performance. Orphan Drug Designation for KPL-387 enhances future growth potential. Increased cash balance supports operational stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kiniksa Pharmaceuticals (KNSA) reported Q3 earnings of $0.23 per share, missing the $0.33 estimate, compared to a loss of $0.18 per share in the same quarter last year.
Why It Matters
Kiniksa Pharmaceuticals' earnings miss indicates potential operational challenges and may impact investor confidence, affecting stock performance and future valuations.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About KNSA Stock
What is Kiniksa Pharmaceuticals International plc's (KNSA) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Kiniksa Pharmaceuticals International plc (KNSA) has a median price target of $55.00. The highest price target is $62.00 and the lowest is $45.00.
Is KNSA stock a good investment in 2026?
According to current analyst ratings, KNSA has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $41.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KNSA stock?
Wall Street analysts predict KNSA stock could reach $55.00 in the next 12 months. This represents a 32.0% increase from the current price of $41.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kiniksa Pharmaceuticals International plc's business model?
Kiniksa Pharmaceuticals focuses on developing clinical-stage product candidates for autoinflammatory conditions. The company generates revenue by advancing its drug pipeline through clinical trials and regulatory approval processes, ultimately aiming to commercialize successful therapies that address significant unmet medical needs.
What is the highest forecasted price for KNSA Kiniksa Pharmaceuticals International plc?
The highest price target for KNSA is $62.00 from at , which represents a 48.8% increase from the current price of $41.67.
What is the lowest forecasted price for KNSA Kiniksa Pharmaceuticals International plc?
The lowest price target for KNSA is $45.00 from Eva Fortea Verdejo at Wells Fargo, which represents a 8.0% increase from the current price of $41.67.
What is the overall KNSA consensus from analysts for Kiniksa Pharmaceuticals International plc?
The overall analyst consensus for KNSA is bullish. Out of 9 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $55.00.
How accurate are KNSA stock price projections?
Stock price projections, including those for Kiniksa Pharmaceuticals International plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 11:22 PM UTC